Objective. To examine the role of polymorphisms in angiotensin converting enzyme (ACE, I/D) and angiotensin II receptor (AT1R, A1166C) in the development of abdominal aortic aneurysm (AAA). Materials and methods. We investigated 250 consecutive patients, 217 males and 33 females (median age 72, range 50-83), undergone AAA elective repair and 250 healthy controls, comparable for sex and age. ACE and AT1R polymorphisms were studied by PCR-RFLP analysis. The genotype distribution was in Hardy-Weinberg equilibrium for all polymorphisms. Results. The genotype distribution and allele frequency of ACE I/D, but not AT1R A1166C polymorphism were significantly different between patients and controls (ACE I/D: pZ0.0002 and p!0.0001, respectively, and AT1R A1166C: pZ0.6 and pZ0.4, respectively). An association between the ACE DD genotype and the predisposition to AAA was found (OR DD vs. IDCIIZ1.9 95% CI 1.3-2.9, p!0.0001). Multivariate analysis adjusted for age, sex, traditional vascular risk factors and other atherosclerotic localizations, showed ACE DD genotype to be independently related to the disease (OR DD vs. IDCIIZ2.4, 95% CI 1.3-4.2 pZ0.003). Conclusions. Our findings document that ACE DD genotype represents a susceptibility factor for AAA.
Introduction
Abdominal aortic aneurysm (AAA) represents a chronic degenerative condition associated with atherosclerosis and characterized by segmental weakening and dilation of the aortic wall. Its pathogenesis involves both genetic and environmental factors, but it has not been completely clarified yet. Experimental studies demonstrate that angiotensin II infusion produces large abdominal aortic aneurysm 1 in animals. Both angiotensin II-forming enzymes, chymase and angiotensin converting enzyme (ACE), are highly expressed in human aneurysmal aorta. 2 Accordingly, increased local angiotensin II formation may play a crucial role in the development of the disease.
The I/D polymorphism in the intron 16 of the angiotensin converting enzyme (ACE) gene and the A1166C polymorphism in the gene encoding for angiotensin II type 1 receptor (AT1R) have been demonstrated to be associated with atherosclerotic lesions in cardiovascular disease. 3 The ACE D allele has been reported to be associated with increased serum levels of circulating enzyme 4 and behaves like a marker of atherosclerotic cardiovascular complications. 5, 6 The 1166C rare variant of the A1166C polymorphism has been associated with aortic stiffness 7, 8 and vascular reactivity, 9 suggesting a biological effect possibly through linkage disequilibrium with another functional polymorphism.
To the best of our knowledge, no data are available regarding the evaluation of ACE and AT1R polymorphisms in patients affected by AAA. This study was carried out in order to document a role for these polymorphisms in the pathogenesis of artery aneurysm and to evaluate their role in normo-and hypertensive patients.
Materials and Methods

Subjects
We studied 250 consecutive patients with AAA referred to the Unit of Vascular Surgery of the University of Florence. AAA was defined as a focal dilation of the abdominal aorta at least 50% larger than expected normal diameter, according to the current report standard. 10 Consanguineous subjects and inflammatory aneurysms were excluded from the study. A group of 250 healthy subjects recruited from partners or friends of patients and comparable for age and gender were used as controls. All controls had no AAA and a negative history of vascular diseases, as evaluated by expert physicians in the frame of the physical examination. Patients and controls were Caucasians from central and southern Italy. All subjects gave informed consent. The study was approved by the local ethics committee. All subjects underwent duplex scanning examination using an Acuson Sequoia Color Duplex System (Mountain View, CA, USA) with a multifrequency convex probe, ranging from 5 to 2 MHz. Ultrasound scanning examination was then confirmed in patients by CTA. Digital subtraction angiography was performed only in patients with concomitant peripheral arterial disease and in candidates for endovascular treatment of AAA when CTA was not satisfactory to evaluate the feasibility for endovascular treatment. Aortic diameter was measured below the origin of renal arteries in both groups. The subjects were considered to have hypertension if they had been diagnosed as hypertensives according to the guidelines of European Society of Hypertension/European Society of Cardiology 11 or were taking antihypertensive drugs. Dyslipidemia was defined according to the Third report of the National Cholesterol Education Program (NCEP-III) 12 and diabetes in agreement with the American Diabetes Association. 13 All patients underwent clinical examinations, electrocardiography, echocardiography and duplex scanning of carotid arteries and ankle/brachial pressure index evaluation. In patients with symptoms of ischemic heart disease, further investigations were performed (echocardiography on drug-induced stress testing, myocardial scintigraphy, and coronary angiography). The severity of carotid stenosis, confirmed by computed tomography angiography, was defined according to the NASCET criteria.
14 Peripheral arterial disease was documented as present if ankle/brachial pressure index was less than 0.9. On the basis of these criteria 71 (28%) patients had clinical evidence of coronary artery disease (CAD), cerebrovascular disease (CVD) was found in 25 patients (10%) and peripheral arterial disease (PAD) in 49 (19%). Aneurysmal size was measured by means of computed tomography.
Detection of ACE and AT1R polymorphisms
Genomic DNA extraction was performed from peripheral blood leucocytes by using a QIAmp Blood Kit (QIAGEN, Hilden, Germany).
The ACE I/D polymorphism was genotyped according to Rigat et al. 15 The DD genotype was subjected to a second PCR amplification without 5% DMSO at an annealing temperature of 67 8C and by using a primer pair that recognises the insertionspecific sequence, in order to reduce underestimation of heterozygotes. 16 The ACE I/D polymorphism consists of the presence/absence of a 287 bp DNA fragment corresponding to an Ala repetitive sequence in the intron 16 of the ACE gene, so determining the insertion (I) and deletion (D) allele. This polymorphism accounts for three genotypes, DD and II homozygotes and ID heterozygote. Because the alleles are codominant with an additive effect on plasma levels, subjects homozygote for the deletion allele have the highest ACE plasma levels, the homozygotes for the insertion allele have the lowest and subjects heterozygotes ID show intermediate levels. The A1166C polymorphism of the AT1R gene was identified by PCR amplification using primers and PCR conditions as described by Katsuja et al. 17 
Statistical analysis
Statistical analysis was performed by using the Statistical Package of Social Sciences (SPSS w ; Chicago, IL, USA) software for Windows (Version 11.5). Data are expressed as median and range. Aortic diameter was expressed as meanGSD. The c 2 -test was used to test for proportions and deviations of genotype distribution from Hardy-Weinberg equilibrium. ACE and AT1R allele frequencies were obtained by direct count. The number of subjects studied was sufficient to detect, with a statistical power of 80% (bZ0.8) and significance value of 0.05 (a), absolute difference in ACE allele frequency. We used a recessive model of inheritance, which assumed the rare allele to be dominant (e.g. ACE DD vs. IDCII). The non-parametric Mann-Whitney test was used for comparisons between single groups. Kruskal-Wallis test was used for comparisons among different groups. The relationship between the two polymorphisms and AAA was determined by univariate logistic regression analysis.
Variables showing, at univariate analysis, a statistically significant association with AAA were introduced in a multivariate model in order to evaluate the association with the disease after adjustment for traditional cardiovascular risk factors. Odds ratio (OR) with 95% confidence interval was determined. A p-value !0.05 was considered to indicate statistical significance.
Results
Demographic and clinical characteristics of the study population are described in Table 1 . We observed significant differences between the two groups for traditional cardiovascular risk factors. Genotype distribution and allele frequency of ACE I/D and AT1R A1166C polymorphisms were in Hardy-Weinberg equilibrium and are reported in Table 2. A significant difference in both genotype distribution and allele frequency between patients and healthy subjects was observed for ACE, but not for AT1R polymorphism.
Univariate logistic regression analysis demonstrated an association of ACE DD genotype and the disease (Table 3 ) (p!0.0001). By determining the odds ratios on the basis of the number of rare alleles, we observed an increased predisposition to AAA with a dose-dependent effect for ACE but not for AT1R polymorphism (Table 3) . Adjusting for age, gender, smoking habit, hypertension, dyslipidemia and other atherosclerotic disease (i.e. CAD, PAD and CVD) ( Table 4) As far as hypertension is considered, a significant difference between hypertensive AAA patients and hypertensive controls (pZ0.04), as well as between normotensive AAA patients and normotensive controls (pZ0.0002) was found. We observed no significant difference (pZ0.2) in the ACE D allele frequency between hypertensive and normotensive patients and hypertensive and normotensive controls (pZ0.8) ( Table 5) .
Aortic diameters were similar among the three genotypes both in ACE and in AT1R polymorphisms and no significant difference in diameters among the subgroups was observed ( Table 6 ). The mean diameter of abdominal aorta in hypertensive patients (6.1G1.2) was comparable (pZ0.4) to that observed in normotensive patients (5.9G1.3).
Discussion
The present study evaluated for the first time the role of both ACE and AT1R genes in the predisposition to AAA. Our results confirmed the role of traditional vascular risk factors (i.e. smoking habit, hypertension and dyslipidemia) in the predisposition to AAA, and provide evidence for a mild, but significant, association with the disease in subjects carrying the ACE D allele. Conversely, we failed to find such a similar influence as regard the AT1R A1166C polymorphism.
ACE D allele has been reported to affect plasma ACE levels, 4 since I allele may have a 'silencer' effect, 18 thereby regulating the production of angiotensin II with a dose-dependent effect (i.e. ID genotype have higher ACE plasma levels than II whereas DD genotype have higher ACE plasma levels than both ID and II genotypes). DD homozygotes subjects had higher levels of ACE compared to II homozygotes, and intermediate levels were observed in heterozygotes ID. 4 Increased angiotensin II plasma levels may lead to the remodelling of vascular tissue. 19 However, the mechanisms responsible for aortic dilation remain to unknown. Experimental data demonstrates a relationship between angiotensin II, atherosclerosis, and aortic aneurysm formation.
1 Angiotensin II promotes hypertension and alters shear stress. 20, 21 Another mechanism by which angiotensin II may affect the vascular tissue remodelling is the activation of growth factors and inflammation either through the induction of cytokines and VCAM-1 expression, 22 or by activating NF-kB-dependent gene expression, 23 or probably by inducing MCP-1 (monocyte chemoattractant protein-1), a product of endothelial and smooth muscle cells expression.
Our results are in keeping with those reported by Pola et al. in Italian population, 24 but at variance with those of a Japanese study. 25 These conflicting findings might be a result of the variable impact that a polymorphism can have on populations with different genetic background. Our data confirms previous results which identified the ACE DD genotype as a risk factor for both cardiac and carotid atherosclerosis. 26, 27 Pola et al. 24 suggested a role for ACE I/D polymorphism in the pathogenesis of AAA in normotensive, but not in hypertensive patients; however, our findings provide evidence of an influence of ACE I/D polymorphism on pathogenesis of AAA, both in normotensive and in hypertensive patients. Hypertension is a known risk factor for AAA and data from literature report conflicting results about the association between ACE I/D polymorphism and hypertension. 28, 29 In our opinion the new feature of our study is the contemporary evaluation of two different genes in the predisposition to AAA. We evaluated the relationship between the ACE and AT1R genes polymorphisms and the aortic diameter, but we did not demonstrate any difference in AAA dilation among genotypes analysed. Yeung et al. 30 failed to find any relationship between ACE gene and rate of AAA expansion; they hypothesised that other components of the RAS may play a role in AAA progression. However, our study, which analysed the relationship between the other components of RAS, such as AT1R gene, and aortic dilation, did not support this hypothesis.
Some limitations can be identified in this study. First, because of its case-control design, the study is unable to determine if ACE polymorphism is causally related to the presence of AAA. The clinical significance of the association between ACE polymorphism and AAA needs to be confirmed by further studies. Secondly, the control group consisted of clinically healthy subjects with no evidence of atherosclerotic disease whereas the optimal comparable control group would be represented by atherosclerotic subjects with no AAA.
In conclusion, this study shows that ACE DD genotype represents a marker of increased susceptibility to AAA. Our results, according to other experimental and clinical studies, 31, 32 could suggest a possible benefit of ACE inhibitors treatment in increasing type III collagen turnover and in AAA wall matrix remodelling, apart from hypertension. The clinical relevance of these findings lays in the possible identification of patients with AAA carrying the ACE D allele, who may exhibit a better response to ACE inhibitors drugs, 33 in order to perform a tailored medical therapy.
Moreover, future prospective study testing the contribution of ACE and AT1R genes in determining the rate of AAA dilation would be worthwhile. Values are expressed in cm.
